Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An announcement from Eton Pharmaceuticals ( (ETON) ) is now available.
On July 8, 2025, Eton Pharmaceuticals announced that its New Drug Application for ET-600, a patented desmopressin oral solution, was accepted for review by the FDA, with a target action date set for February 25, 2026. If approved, ET-600 will be the only oral liquid option for treating central diabetes insipidus in pediatric patients, addressing a significant unmet need and representing a potential high-value product launch for Eton in early 2026.
The most recent analyst rating on (ETON) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on Eton Pharmaceuticals stock, see the ETON Stock Forecast page.
Spark’s Take on ETON Stock
According to Spark, TipRanks’ AI Analyst, ETON is a Neutral.
Eton Pharmaceuticals’ overall stock score is driven by a mixed financial performance with strong revenue growth but profitability challenges. Technical analysis indicates bearish momentum, while valuation metrics reflect a lack of profitability. Earnings call insights and recent corporate events provide a positive outlook, contributing to the overall score.
To see Spark’s full report on ETON stock, click here.
More about Eton Pharmaceuticals
Eton Pharmaceuticals is an innovative pharmaceutical company that focuses on developing and commercializing treatments for rare diseases. The company currently offers eight commercial rare disease products and has five additional product candidates in late-stage development.
Average Trading Volume: 427,481
Technical Sentiment Signal: Buy
Current Market Cap: $385.9M
Learn more about ETON stock on TipRanks’ Stock Analysis page.